Topical calcitriol (1,25-dihydroxyvitamin D3) treatment of psoriasis: An immunohistological evaluation

Acta Dermato-Venereologica

Volumn 77, Issue 4, 1997, Pages 268-272

  Reichrath, J ^a,b   Perez, A ^a   Muller S M ^b   Chen, T C ^a   Kerber, A ^b   Bahmer, F A ^b   Holick, M F ^a  

^a BOSTON UNIVERSITY MEDICAL CENTER   (United States)

^b SAARLAND UNIVERSITY   (Germany)

Author keywords

Calcitriol treatment; Immunohistochemistry

Indexed keywords

CALCITRIOL;

ADULT; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; DRUG EFFICACY; EPIDERMIS CELL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOLOGY; MALE; PRIORITY JOURNAL; PSORIASIS; SKIN BIOPSY; TOPICAL DRUG ADMINISTRATION;

ADMINISTRATION, TOPICAL; ANTIGENS, CD1; CALCITRIOL; CELL DIFFERENTIATION; CELL DIVISION; HUMANS; IMMUNOHISTOCHEMISTRY; INTERLEUKIN-8; KERATINOCYTES; KERATINS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTEIN PRECURSORS; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; SKIN; TRANSGLUTAMINASES;

EID: 0030754642     PISSN: 00015555     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Holick MF, Chen ML, Kong XF, Sanan DK. Clinical uses for calciotropic hormones 1, 25-dihydroxyvitamin D, and parathyroid-hormone related peptide in dermatology: a new perspective. J Invest Dermatol 1996; 1: 1-9.
2. Bourke JF, Berth-Jones J, Igbal SJ, Hutchinson PE. High-dose topical calcipotriol in the treatment of extensive psoriasis vulgaris. Br J Dermatol 1993; 129: 74-76.
3. 3) for the treatment of psoriasis. Br J Dermatol 1996; 134: 238-246.
4. Kragballe K, Beck HI, Sogaard H. Improvement of psoriasis by a topical vitamin D analogue (MC 903) in a double blind study. Br J Dermatol 1988; 119: 223-230.
5. 3 in intestinal tract, stomach, kidney, skin, pituary and parathyroid. Science 1979; 206: 1189-1190.
6. 3 receptors in normal and psoriatic skin. J Invest Dermatol 1991; 97: 230-239.
7. Baker AR, Mc Donnell DP, Hughes M, Crisp TM, Mangelsdorf DJ, Haussler MR, et al. Cloning and expression of full-length cDNA encoding human vitamin D receptor. Proc Natl Acad Sci USA 1988; 85: 3294-3298.
8. 3 increases calcium and phosphatidylinositol metabolism in differentiating cultured human keratinocytes. J Nutr Biochem 1990; 1: 81-87.
9. 3 increases intra-cellular calcium in human keratinocytes. Br J Dermatol 1991; 124: 12230-12235.
10. 3 in the growth and differentiation of human keratinocytes. Acta Biochem Biophys 1991; 1092: 311-318.
11. 3 on the morphologic and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol 1986; 86: 709-714.
12. Rigby WFC. The immunobiology of vitamin D. Immunol Today 1988; 9: 54-58.
13. Texerau M, Viac J. Vitamin D, immune system and skin. Eur J Dermatol 1992; 2: 258-264.
14. Hall PA, Levison DA, Woods AL, Yu CC-W, Kellock DB, Watkins JA, et al. Proliferating cell nuclear antigen (PCNA) immunolocalization in paraffin sections: an index of cell proliferation with evidence of deregulated expressions in some neoplasms. J Pathol 1990; 162: 285-294.
15. Huszar M, Gigi-Leitner O, Moll R, Franke WW, Geiger B. Monoclonal antibodies to various acidic (type I) cytokeratins of stratified epithelia. Selective markers for stratification and squamous cell carcinomas. Differentiation 1986; 31: 141-153.
16. Kallionen M, Koivukangas V, Jarvinen M, Oikarinen A. Expression of cyto-keratins in regenerating human epidermis. Br J Dermatol 1995; 133: 830-835.
17. Gigi-Leitner I, Geiger B, Levy R, Czernobilsky B. Cytokeratin expression in squamous metaplasia of the human uterine cervix. Differentiation 1986; 31: 191-205.
18. Kanitakis J, Zambruno G, Viac J, Thivolet J. Involucrin expression in keratinization disorders of the skin-a preliminary study. Br J Dermatol 1987; 117: 479-486.
19. Schroeder WT, Thacher SM, Stewart-Galetka S, Annarelle M, Chema D, Siciliano MJ, et al. Type I keratinocyte transglutaminase: expression in human skin and psoriasis. J Invest Dermatol 1992; 99: 27-34.
20. Reichrath J, Müller SM, Kerber A, Baum HP, Bahmer FA. Biological effects of topical calcipotriol (MC 903) treatment in psoriatic skin. J Am Acad Dermatol 1997; 86: 19-28.
21. Sticherling M, Bornscheuer E, Schröder JM, Christophers E. Localisation of neutrophil-activating-peptide-1/IL-8 immunoreactivity in normal and psoriatic skin. J Invest Dermatol 1991; 96: 26-30.
22. 3: a cell biological study. Br J Dermatol 1993; 128: 666-673.
23. Gottlieb AB. Immunologic mechanisms in psoriasis. J Am Acad Dermatol 1988; 18: 1376-1380.
24. Valdimarsson H, Baker BS, Jonsdottir I, Fry L. Psoriasis: a disease of abnormal keratinocyte proliferation induced by T-lymphocytes. Immunol Today 1988; 7: 256-259.
25. 3 is a potent regulator of interleukin-1 induced interleukin-8 expression and production. Biochem Biophys Res Commun 1991; 176: 1020-1026.
26. 3. Immunology 1991; 72: 61-66.
27. De Jong EMGJ, Van de Kerkhof PCM. Simultaneous assessment of inflammation and epidermal proliferation in psoriatic plaques during long term treatment with vitamin D analogue MC 903: modulations and interrelations. Br J Dermatol 1991; 124: 221-229.
28. 3 analogue MC 903 and betamethasone. Br J Dermatol 1990; 123: 291-295.
29. Berth-Jones J, Fletcher A, Hutchinson PE. Epidermal cytokeratin and immunocyte response during treatment of psoriasis with calcipotriol and betamethasone valerate. Br J Dermatol 1992; 126: 356-361.